Thus, the data presented here could perhaps have clinical implications in that RAD51 and RPA might be useful diagnostic markers for pre-malignant (DCIS) breast cancers and, in particular, for screening breast cancers for mutations in the BRCA1 BRCT domain that result in hyper-recombination. The gene discussed is BRCA1; the disease is breast carcinoma.